BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Cancer / Oncology

C-Ray Therapeutics Commends Biokin on NMPA Approval for Groundbreaking [177Lu]-BL-ARC001 Radiopharmaceutical

C-Ray Therapeutics (Chengdu) Co.,Ltd proudly congratulates its strategic partner, Biokin Pharmaceutical, on receiving implied approval from the N...

October 13, 2025 | News

Kazia Therapeutics Partners with QIMR Berghofer to Develop First-in-Class PD-L1 Degrader NDL2

Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused drug development company, announced an exclusive collaboration and in-licensing agreem...

October 09, 2025 | News

Redefining Cancer Care in Southeast Asia: Siemens Healthineers’ Fabrice Leguet on Turning Awareness into Action

Cancer care in Southeast Asia stands at a critical crossroads. While awareness of early detection is high, the translation into meaningful action remains p...

October 01, 2025 | Interaction | By arcilla.fran@biopharmaapac.com

Daiichi Sankyo and AstraZeneca’s ENHERTU delivers second positive phase 3 win in HER2 positive early breast cancer

Second positive phase 3 trial of Daiichi Sankyo and AstraZeneca’s ENHERTU in HER2 positive early breast cancer reinforces its potential to become...

September 30, 2025 | News

Noul Secures FDA Registration for miLab™ CER Cervical Cancer Diagnostic, Paving Way for US Market Entry

Noul Co., Ltd. (CEO: David Lim), a medical AI company specializing in blood and cancer diagnostics, announced that FDA registration has been completed...

September 26, 2025 | News

Lunit and CellCarta Form Global Partnership to Advance AI-Powered Pathology in Clinical Trials

Lunit , a leading provider of AI for cancer diagnostics and biomarkers for oncology therapeutics, announced a strategic partnership with CellCarta, a globa...

September 25, 2025 | News

Lunit and Agilent Forge Collaboration to Develop AI-Powered Companion Diagnostics

Collaboration combines Lunit's AI expertise with Agilent's diagnostic leadership to revolutionize biomarker testing and enhance precision medicine capabili...

September 23, 2025 | News

Johnson & Johnson’s Amivantamab–Lazertinib Combo Extends Survival Beyond Four Years in Asia NSCLC Cohort

Median overall survival in Asia cohort is projected to exceed four years, demonstrating a durable benefit and surpassing osimertinib monotherapy by more th...

September 17, 2025 | News

Japan Approves Novocure’s Optune Lua for Concurrent Use with PD-1/PD-L1 Inhibitors in Advanced NSCLC

Optune Lua is now approved for use concurrently with PD-1/PD-L1 inhibitors in adult patients with unresectable advanced/recurrent NSCLC who progressed on...

September 17, 2025 | News

Pfizer Advances Australian-Discovered KAT6 Inhibitor PF-07248144 into Phase 3 Trial for Advanced Breast Cancer

Australian biotechnology investment and commercialisation incubator, Oncology One Pty Ltd, is pleased to report that PF-07248144, Pfizer Inc's clinica...

September 16, 2025 | News

Biostar Pharma Doses First Patients in Two Global Phase II/III Trials of Oral Utidelone Capsule for Gastric and Ovarian Cancers

Biostar Pharma, Inc., the US subsidiary of Beijing Biostar Pharmaceuticals Co., Ltd. ("Biostar", Stock Code: 2563.HK) which is a synthetic biolo...

September 16, 2025 | News

Kazia’s Paxalisib Disrupts Circulating Tumour Cell Clusters in HER2-Positive Metastatic Breast Cancer Study

Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused drug development company, today announced new findings from a collaborative research program...

September 12, 2025 | News

Siemens Healthineers–YouGov Survey Reveals Fragmented Cancer Care Pathway in Southeast Asia, Underscoring Need for Integrated Solutions

YouGov survey finds strong belief in value of early detection (78%) but low screening uptake (26%) 80% of respondents aware post-treatment care exists...

September 10, 2025 | Report

XtalPi and PharmaEngine Advance AI-Designed PRMT5 Inhibitor PEP08 into Phase 1 Trials for Solid Tumours

XtalPi Inc. (Stock Code: 2228.HK) has announced that PEP08, a next-generation PRMT5 inhibitor candidate developed through its AI drug discovery collaborati...

September 10, 2025 | News

Stay Connected